20 results on '"Rhoades JA"'
Search Results
2. Gli2 Overexpression Alters the Differentiation Status of Dedifferentiated Liposarcoma Cells and Results in an Immunosuppressive Myeloid Phenotype in Orthotopic Tumors.
- Author
-
Bennett NE, Beadle EP, Parker DV, Coe EJ, Cottam MA, Baum JE, Miller JS, Serrenho JA, and Rhoades JA
- Abstract
Sarcomas are a rare classification of tumor derived from tissues of mesenchymal origin including bone, fat, muscle, cartilage, and blood vessels. These tumors often grow rapidly and have limited treatment options with few significant therapeutic advances in recent years. Liposarcomas (LPSs), the most common type of malignant soft tissue sarcoma, are derived from mesenchymal progenitors that have undergone an adipogenic lineage commitment compared to their multipotent counterparts. Interestingly, the grade of differentiation within LPS can vary highly, and the differentiation status of these tumors can drastically affect prognosis and likelihood of metastasis, making tumor differentiation a potential mechanism to target in liposarcoma development. Here, we show that overexpression of the Hedgehog transcription factor Gli2 in dedifferentiated liposarcoma (DDLPS) cells represses adipogenic differentiation while simultaneously activating markers of osteoblast differentiation in vitro . In addition, we observed marked differences in cytokine expression and secretion, prompting us to perform orthotopic fat pad injections of control and Gli2 overexpressing DDLPS cells. Using flow cytometry, we observed distinct changes in fat pad macrophage populations, with a particular increase in M2-like macrophages. Taken together, we find that overexpression of Gli2 in DDLPS cells alters their differentiation capacity and interactions between tumor cells and macrophages, highlighting a novel role for this developmental transcription factor in liposarcoma pathogenesis.
- Published
- 2024
- Full Text
- View/download PDF
3. Pharmacologic Hedgehog inhibition modulates the cytokine profile of osteolytic breast cancer cells.
- Author
-
Bennett NE, Parker DV, Mangano RS, Baum JE, Northcutt LA, Miller JS, Beadle EP, and Rhoades JA
- Abstract
The establishment and progression of bone metastatic breast cancer is supported by immunosuppressive myeloid populations that enable tumor growth by dampening the innate and adaptive immune response. Much work remains to understand how to target these tumor-myeloid interactions to improve treatment outcomes. Noncanonical Hedgehog signaling is an essential component of bone metastatic tumor progression, and prior literature suggests a potential role for Hedgehog signaling and its downstream effector Gli2 in modulating immune responses. In this work, we sought to identify if inhibition of noncanonical Hedgehog signaling alters the cytokine profile of osteolytic breast cancer cells and the subsequent communication between the tumor cells and myeloid cells. Examination of large patient databases revealed significant relationships between Gli2 expression and expression of markers of myeloid maturation and activation as well as cytokine expression. We found that treatment with HPI-1 reduced tumor cell expression of numerous cytokine genes, including CSF1 , CSF2 , and CSF3 , as well as CCL2 and IL6 . Secreted CSF-1 (M-CSF) was also reduced by treatment. Changes in tumor-secreted factors resulted in polarization of THP-1 monocytes toward a proinflammatory phenotype, characterized by increased CD14 and CD40 surface marker expression. We therefore propose M-CSF as a novel target of Hedgehog inhibition with potential future applications in altering the immune microenvironment in addition to its known roles in reducing tumor-induced bone disease., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
4. Targeting hedgehog-driven mechanisms of drug-resistant cancers.
- Author
-
Miller JS, Bennett NE, and Rhoades JA
- Abstract
Due to the cellular plasticity that is inherent to cancer, the acquisition of resistance to therapy remains one of the biggest obstacles to patient care. In many patients, the surviving cancer cell subpopulation goes on to proliferate or metastasize, often as the result of dramatically altered cell signaling and transcriptional pathways. A notable example is the Hedgehog (Hh) signaling pathway, which is a driver of several cancer subtypes and aberrantly activated in a wide range of malignancies in response to therapy. This review will summarize the field's current understanding of the many roles played by Hh signaling in drug resistance and will include topics such as non-canonical activation of Gli proteins, amplification of genes which promote tolerance to chemotherapy, the use of hedgehog-targeted drugs and tool compounds, and remaining gaps in our knowledge of the transcriptional mechanisms at play., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Miller, Bennett and Rhoades.)
- Published
- 2023
- Full Text
- View/download PDF
5. Bioinformatics Screen Reveals Gli-Mediated Hedgehog Signaling as an Associated Pathway to Poor Immune Infiltration of Dedifferentiated Liposarcoma.
- Author
-
Beadle EP, Bennett NE, and Rhoades JA
- Abstract
Liposarcomas are the most diagnosed soft tissue sarcoma, with most cases consisting of well-differentiated (WDLPS) or dedifferentiated (DDLPS) histological subtypes. While both tumor subtypes can have clinical recurrence due to incomplete resections, DDLPS often has worse prognosis due to a higher likelihood of metastasis compared to its well-differentiated counterpart. Unfortunately, targeted therapeutic interventions have lagged in sarcoma oncology, making the need for molecular targeted therapies a promising future area of research for this family of malignancies. In this work, previously published data were analyzed to identify differential pathways that may contribute to the dedifferentiation process in liposarcoma. Interestingly, Gli-mediated Hedgehog signaling appeared to be enriched in dedifferentiated adipose progenitor cells and DDLPS tumors, and coincidentally Gli1 is often co-amplified with MDM2 and CDK4, given its genomic proximity along chromosome 12q13-12q15. However, we find that Gli2, but not Gli1, is differentially expressed between WDLPS and DDLPS, with a noticeable co-expression signature between Gli2 and genes involved in ECM remodeling. Additionally, Gli2 co-expression had a noticeable transcriptional signature that could suggest Gli-mediated Hedgehog signaling as an associated pathway contributing to poor immune infiltration in these tumors.
- Published
- 2023
- Full Text
- View/download PDF
6. Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction.
- Author
-
Florian DC, Bennett NE, Odziomek M, Baljon JJ, Wehbe M, Merkel AR, Fischer MA, Savona MR, Rhoades JA, Guelcher SA, and Wilson JT
- Subjects
- Mice, Animals, Bone Marrow, Cytokines, Phenotype, Tumor Microenvironment, Neoplasms, Nanoparticles
- Abstract
When breast cancer metastasizes to bone, treatment options are limited. Failure to treat bone metastases is thought to be due to therapy-resistant features of the bone marrow microenvironment. Using a murine model of bone metastatic mammary carcinoma, we demonstrate that systemic delivery of polymer nanoparticles loaded with cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) inhibited tumor growth and bone destruction after 7 days of treatment. Each dose of STING-activating nanoparticles trafficked to the bone marrow compartment and was retained within the tumor microenvironment for over 24 hours, enhancing antitumor immunity through proinflammatory cytokine production and early T-cell activation. While acquired resistance mechanisms, including increased levels of immunosuppressive cytokines and the infiltration of regulatory T cells, ultimately limited antitumor efficacy after 2 weeks of treatment, bone protective effects remained. Overall, these studies demonstrate that STING pathway activation, here enabled using a nanomedicine approach to enhance CDN delivery to bone metastatic sites, can reprogram the immune contexture of the bone marrow to an antitumor phenotype that inhibits bone colonization of metastatic breast cancer cells and protects from tumor-mediated bone destruction., Significance: Bone metastases are difficult to treat due to the inaccessibility of the bone marrow compartment and the immunosuppressive microenvironment that protects resident stem cells. Packaging a STING agonist into a nanoparticle that enables systemic administration and drug accumulation at tumor sites overcomes both barriers to stymie metastatic breast cancer growth., Competing Interests: N.E. Bennett reports grants from NIH during the conduct of the study. A.R. Merkel reports grants from Verteran's Administration and non-financial support from Vanderbilt University Medical Center during the conduct of the study; grants from NIH Clinical and Translational Science Award and National Center for Advancing Translational Sciences outside the submitted work. M.A. Fischer reports grants from Incyte Corporation during the conduct of the study. M.R. Savona reports grants from ALX Oncology, Astex, Incyte, Takeda, TG Therapeutics; personal fees from BMS, CTI, Forma, Geron, Novartis, Sierra Oncology, Taiho; personal fees and other from Ryvu and Karyopharm outside the submitted work. J.A. Rhoades reports grants from Veterans Administration during the conduct of the study. S.A. Guelcher reports grants from Incyte Corporation during the conduct of the study. J.T. Wilson reports a patent to 10,696,985 issued and a patent to PCT/US2019/058945 pending. No disclosures were reported by the other authors., (© 2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
7. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations.
- Author
-
Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D'Oronzo S, Guise TA, and Van Poznak C
- Abstract
Optimum management of patients with cancer during the COVID-19 pandemic has proved extremely challenging. Patients, clinicians and hospital authorities have had to balance the risks to patients of attending hospital, many of whom are especially vulnerable, with the risks of delaying or modifying cancer treatment. Those whose care has been significantly impacted include patients suffering from the effects of cancer on bone, where delivering the usual standard of care for bone support has often not been possible and clinicians have been forced to seek alternative options for adequate management. At a virtual meeting of the Cancer and Bone Society in July 2020, an expert group shared experiences and solutions to this challenge, following which a questionnaire was sent internationally to the symposium's participants, to explore the issues faced and solutions offered. 70 respondents, from 9 countries (majority USA, 39%, followed by UK, 19%) included 50 clinicians, spread across a diverse range of specialties (but with a high proportion, 64%, of medical oncologists) and 20 who classified themselves as non-clinical (solely lab-based). Spread of clinician specialty across tumour types was breast (65%), prostate (27%), followed by renal, myeloma and melanoma. Analysis showed that management of metastatic bone disease in all solid tumour types and myeloma, adjuvant bisphosphonate breast cancer therapy and cancer treatment induced bone loss, was substantially impacted. Respondents reported delays to routine CT scans (58%), standard bone scans (48%) and MRI scans (46%), though emergency scans were less affected. Delays in palliative radiotherapy for bone pain were reported by 31% of respondents with treatments often involving only a single dose without fractionation. Delays to, or cancellation of, prophylactic surgery for bone pain were reported by 35% of respondents. Access to treatments with intravenous bisphosphonates and subcutaneous denosumab was a major problem, mitigated by provision of drug administration at home or in a local clinic, reduced frequency of administration or switching to oral bisphosphonates taken at home. The questionnaire also revealed damaging delays or complete stopping of both clinical and laboratory research. In addition to an analysis of the questionnaire, this paper presents a rationale and recommendations for adaptation of the normal guidelines for protection of bone health during the pandemic., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
8. 3D Bone Morphology Alters Gene Expression, Motility, and Drug Responses in Bone Metastatic Tumor Cells.
- Author
-
Dadwal UC, Merkel AR, Page JM, Kwakwa KA, Kessler M, and Rhoades JA
- Subjects
- Animals, Cell Line, Tumor, Female, Humans, Mice, Mice, Nude, Neoplasm Metastasis, Bone Neoplasms drug therapy, Bone Neoplasms metabolism, Bone Neoplasms pathology, Cell Movement drug effects, Gene Expression Regulation, Neoplastic drug effects, Models, Biological, Neoplasm Proteins biosynthesis, Pyridines pharmacology, Thiophenes pharmacology, Tissue Scaffolds chemistry
- Abstract
Patients with advanced skeletal metastases arising from primary cancers including breast, lung, and prostate suffer from extreme pain, bone loss, and frequent fractures. While the importance of interactions between bone and tumors is well-established, our understanding of complex cell-cell and cell-microenvironment interactions remains limited in part due to a lack of appropriate 3D bone models. To improve our understanding of the influence of bone morphometric properties on the regulation of tumor-induced bone disease (TIBD), we utilized bone-like 3D scaffolds in vitro and in vivo. Scaffolds were seeded with tumor cells, and changes in cell motility, proliferation, and gene expression were measured. Genes associated with TIBD significantly increased with increasing scaffold rigidity. Drug response differed when tumors were cultured in 3D compared to 2D. Inhibitors for Integrin β3 and TGF-β Receptor II significantly reduced bone-metastatic gene expression in 2D but not 3D, while treatment with the Gli antagonist GANT58 significantly reduced gene expression in both 2D and 3D. When tumor-seeded 3D scaffolds were implanted into mice, infiltration of myeloid progenitors changed in response to pore size and rigidity. This study demonstrates a versatile 3D model of bone used to study the influence of mechanical and morphometric properties of bone on TIBD.
- Published
- 2020
- Full Text
- View/download PDF
9. Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction.
- Author
-
Vanderburgh J, Hill JL, Gupta MK, Kwakwa KA, Wang SK, Moyer K, Bedingfield SK, Merkel AR, d'Arcy R, Guelcher SA, Rhoades JA, and Duvall CL
- Subjects
- Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Bone Neoplasms diagnostic imaging, Bone Neoplasms secondary, Cell Line, Tumor, Cell Proliferation drug effects, Disease Models, Animal, Drug Screening Assays, Antitumor, Female, Humans, Ligands, Mice, Mice, Inbred C57BL, Mice, Knockout, Optical Imaging, Particle Size, Polymers chemical synthesis, Polymers chemistry, Pyridines chemistry, Surface Properties, Thiophenes chemistry, X-Ray Microtomography, Antineoplastic Agents pharmacology, Bone Neoplasms drug therapy, Nanoparticles chemistry, Polymers pharmacology, Pyridines pharmacology, Thiophenes pharmacology
- Abstract
Breast cancer patients are at high risk for bone metastasis. Metastatic bone disease is a major clinical problem that leads to a reduction in mobility, increased risk of pathologic fracture, severe bone pain, and other skeletal-related events. The transcription factor Gli2 drives expression of parathyroid hormone-related protein (PTHrP), which activates osteoclast-mediated bone destruction, and previous studies showed that Gli2 genetic repression in bone-metastatic tumor cells significantly reduces tumor-induced bone destruction. Small molecule inhibitors of Gli2 have been identified; however, the lipophilicity and poor pharmacokinetic profile of these compounds have precluded their success in vivo . In this study, we designed a bone-targeted nanoparticle (BTNP) comprising an amphiphilic diblock copolymer of poly[(propylene sulfide)- block -(alendronate acrylamide- co - N , N -dimethylacrylamide)] [PPS- b -P(Aln- co -DMA)] to encapsulate and preferentially deliver a small molecule Gli2 inhibitor, GANT58, to bone-associated tumors. The mol % of the bisphosphonate Aln in the hydrophilic polymer block was varied in order to optimize BTNP targeting to tumor-associated bone by a combination of nonspecific tumor accumulation (presumably through the enhanced permeation and retention effect) and active bone binding. Although 100% functionalization with Aln created BTNPs with strong bone binding, these BTNPs had highly negative zeta-potential, resulting in shorter circulation time, greater liver uptake, and less distribution to metastatic tumors in bone. However, 10 mol % of Aln in the hydrophilic block generated a formulation with a favorable balance of systemic pharmacokinetics and bone binding, providing the highest bone/liver biodistribution ratio among formulations tested. In an intracardiac tumor cell injection model of breast cancer bone metastasis, treatment with the lead candidate GANT58-BTNP formulation decreased tumor-associated bone lesion area 3-fold and increased bone volume fraction in the tibiae of the mice 2.5-fold. Aln conferred bone targeting to the GANT58-BTNPs, which increased GANT58 concentration in the tumor-associated bone relative to untargeted NPs, and also provided benefit through the direct antiresorptive therapeutic function of Aln. The dual benefit of the Aln in the BTNPs was supported by the observations that drug-free Aln-containing BTNPs improved bone volume fraction in bone-tumor-bearing mice, while GANT58-BTNPs created better therapeutic outcomes than both unloaded BTNPs and GANT58-loaded untargeted NPs. These findings suggest GANT58-BTNPs have potential to potently inhibit tumor-driven osteoclast activation and resultant bone destruction in patients with bone-associated tumor metastases.
- Published
- 2020
- Full Text
- View/download PDF
10. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.
- Author
-
Vanderburgh JP, Kwakwa KA, Werfel TA, Merkel AR, Gupta MK, Johnson RW, Guelcher SA, Duvall CL, and Rhoades JA
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Apoptosis drug effects, Bone Neoplasms secondary, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Drug Carriers chemistry, Drug Carriers pharmacokinetics, Drug Liberation, Female, Gene Expression Regulation, Neoplastic, Humans, Mammary Neoplasms, Animal pathology, Mesenchymal Stem Cells drug effects, Mice, Inbred C57BL, Mice, Knockout, Mice, Nude, Nanoparticles chemistry, Osteogenesis drug effects, Polymers administration & dosage, Polymers chemistry, Polymers pharmacokinetics, Pyridines chemistry, Pyridines pharmacokinetics, Thiophenes chemistry, Thiophenes pharmacokinetics, Zinc Finger Protein Gli2 antagonists & inhibitors, Zinc Finger Protein Gli2 genetics, Antineoplastic Agents administration & dosage, Bone Neoplasms drug therapy, Drug Carriers administration & dosage, Mammary Neoplasms, Animal drug therapy, Nanoparticles administration & dosage, Pyridines administration & dosage, Thiophenes administration & dosage
- Abstract
Solid tumors frequently metastasize to bone and induce bone destruction leading to severe pain, fractures, and other skeletal-related events (SREs). Osteoclast inhibitors such as bisphosphonates delay SREs but do not prevent skeletal complications or improve overall survival. Because bisphosphonates can cause adverse side effects and are contraindicated for some patients, we sought an alternative therapy to reduce tumor-associated bone destruction. Our previous studies identified the transcription factor Gli2 as a key regulator of parathyroid hormone-related protein (PTHrP), which is produced by bone metastatic tumor cells to promote osteoclast-mediated bone destruction. In this study, we tested the treatment effect of a Gli antagonist GANT58, which inhibits Gli2 nuclear translocation and PTHrP expression in tumor cells. In initial testing, GANT58 did not have efficacy in vivo due to its low water solubility and poor bioavailability. We therefore developed a micellar nanoparticle (NP) to encapsulate and colloidally stabilize GANT58, providing a fully aqueous, intravenously injectable formulation based on the polymer poly(propylene sulfide)
135 -b-poly[(oligoethylene glycol)9 methyl ether acrylate]17 (PPS135 -b-POEGA17 ). POEGA forms the hydrophilic NP surface while PPS forms the hydrophobic NP core that sequesters GANT58. In response to reactive oxygen species (ROS), PPS becomes hydrophilic and degrades to enable drug release. In an intratibial model of breast cancer bone metastasis, treatment with GANT58-NPs decreased bone lesion area by 49% (p<.01) and lesion number by 38% (p<.05) and resulted in a 2.5-fold increase in trabecular bone volume (p<.001). Similar results were observed in intracardiac and intratibial models of breast and lung cancer bone metastasis, respectively. Importantly, GANT58-NPs reduced tumor cell proliferation but did not alter mesenchymal stem cell proliferation or osteoblast mineralization in vitro, nor was there evidence of cytotoxicity after repeated in vivo treatment. Thus, inhibition of Gli2 using GANT58-NPs is a potential therapy to reduce bone destruction that should be considered for further testing and development toward clinical translation., (Published by Elsevier B.V.)- Published
- 2019
- Full Text
- View/download PDF
11. Pilot study of a high-frequency school-based hearing screen to detect adolescent hearing loss.
- Author
-
Sekhar DL, Zalewski TR, Ghossaini SN, King TS, Rhoades JA, Czarnecki B, Grounds S, Deese B, Barr AL, and Paul IM
- Subjects
- Adolescent, Audiology methods, Audiometry methods, Calibration, Female, Hearing Loss, High-Frequency diagnosis, Hearing Tests standards, Humans, Male, Mass Screening, Pennsylvania, Pilot Projects, Research Design, School Health Services, Schools, Hearing Loss diagnosis, Hearing Tests methods
- Abstract
Objective: Like most of the United States, school-based hearing screening in Pennsylvania focuses on low-frequency, conductive hearing losses typical for young children, rather than the high-frequency, noise-induced hearing loss more prevalent among adolescents. The objective of this study was to compare the sensitivity and specificity of current school hearing screening in Pennsylvania with hearing screening including high frequencies, designed to detect adolescent hearing loss., Setting: A single public high school., Methods: In the Autumn of 2011 the high-frequency screen was delivered alongside the Pennsylvania school screen for students in the 11(th) grade. Screening referrals and a subset of passes returned for "gold standard" testing with audiology in a sound treated booth, in order to determine the sensitivity and specificity of the screening tests., Results: Of 282 participants, five (2%) were referred on the Pennsylvania school screen, and 85 (30%) were referred on the high-frequency screen. Of the 48 who returned for gold standard testing with audiology, hearing loss was diagnosed in 9/48 (19%). Sensitivity of the Pennsylvania and high-frequency screens were 13% (95% confidence interval [CI] 0-53%) and 100% (95% CI 66-100%) respectively. Specificity of the Pennsylvania and high-frequency screens were 97% (95% CI 87-100%) and 49% (95% CI 32-65%) respectively., Conclusions: Current school hearing screens have low sensitivity for detection of adolescent hearing loss. Modifying school-based protocols may be warranted to best screen adolescents, and make optimal use of school nurse time and effort.
- Published
- 2014
- Full Text
- View/download PDF
12. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
- Author
-
Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, and Markowitz JS
- Subjects
- Antiviral Agents chemistry, Atazanavir Sulfate, Carbamates chemistry, Carbamates pharmacology, Carboxylic Ester Hydrolases chemistry, Carboxylic Ester Hydrolases metabolism, Drug Interactions, Furans, Humans, Kinetics, Models, Molecular, Nelfinavir chemistry, Nelfinavir pharmacology, Oligopeptides chemistry, Oligopeptides pharmacology, Protease Inhibitors chemistry, Pyridines chemistry, Pyridines pharmacology, Quantitative Structure-Activity Relationship, Ritonavir chemistry, Ritonavir pharmacology, Saquinavir chemistry, Saquinavir pharmacology, Sulfonamides chemistry, Sulfonamides pharmacology, Antiviral Agents pharmacology, Carboxylic Ester Hydrolases antagonists & inhibitors, Protease Inhibitors pharmacology
- Abstract
Purpose: To predict and determine whether the protease inhibitors (PIs) nelfinavir, amprenavir, atazanavir, ritonavir, and saquinavir could serve as metabolic inhibitors of the human CES1 (hCES1) using both molecular modeling techniques and in vitro inhibition assays., Methods: Initially, a molecular modeling approach was utilized to predict whether the selected PIs could serve as hCES1 inhibitors. The inhibitory effects of these PIs on hCES1 activity were then further evaluated utilizing previously established in vitro assay., Results: Pharmacophore and 2D-QSAR modeling predicted that nelfinavir would serve as a potent hCES1 inhibitor. This hypothesis was validated by in vitro hCES1 inhibition studies. Other PIs (amprenavir, atazanavir, ritonavir, saquinavir) were evaluated and also shown to be hCES1 inhibitors in vitro, although substantially less potent relative to nelfinavir., Conclusion: Computational molecular modeling is a valid approach to identify potential hCES1 inhibitors as candidates for further assessment using validated in vitro techniques. DDIs could occur when nelfinavir is co-administered with drugs metabolized by hCES1.
- Published
- 2012
- Full Text
- View/download PDF
13. The cost of being a woman: a national study of health care utilization and expenditures for female-specific conditions.
- Author
-
Kjerulff KH, Frick KD, Rhoades JA, and Hollenbeak CS
- Subjects
- Adult, Analysis of Variance, Cross-Sectional Studies, Female, Humans, Middle Aged, Prevalence, Primary Health Care statistics & numerical data, Quality of Life, Surveys and Questionnaires, United States epidemiology, Women's Health Services statistics & numerical data, Cost of Illness, Health Care Costs statistics & numerical data, Primary Health Care economics, Women's Health economics, Women's Health Services economics
- Abstract
Purpose: An important component of women's health care is for conditions that are exclusive to women, yet little research has addressed the economic impact of health care for these conditions. The purpose of this study was to describe health care utilization for female-specific conditions, the incremental expenditures attributable to these conditions, and the overall incremental expenditures across the lifespan., Methods: We analyzed 3 years of a nationally representative survey of the US noninstitutionalized population, the 2000-2002 National Medical Expenditure Panel Survey, which included 25,361 females aged > or =14, representing 38,170 person-years., Results: More than one fifth of women (21.2%) reported having a female-specific condition during a 1-year period, the most common of which were gynecologic disorders (7.4%); pregnancy-related conditions (6.4%); and menopausal symptoms (5.3%). The mean increment in annual total expenditures attributable to female-specific conditions ranged from $483 for menopausal disorders to $3,896 for female cancers. The annual total health care expenditures of women with female-specific conditions were estimated to be $108 billion, of which >40% ($43.3 billion) was attributable to female-specific conditions. Women with female-specific conditions who had no health insurance were less likely to have visited a doctor (p = .0002), filled a prescription (p = .001), and been hospitalized (p = .0001) for these conditions, but more likely to have visited an emergency department (p = .02) seeking treatment for these conditions., Conclusions: In this nationally representative sample of American women aged > or =14, female-specific conditions were common and substantially increased costs of health care.
- Published
- 2007
- Full Text
- View/download PDF
14. Trends in nursing home expenses, 1987 and 1996.
- Author
-
Rhoades JA and Sommers JP
- Subjects
- Activities of Daily Living, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Financing, Personal, Health Expenditures statistics & numerical data, Humans, Infant, Medicare, Mental Health, Middle Aged, Poverty, United States, Health Expenditures trends, Nursing Homes economics
- Abstract
This article presents data about expenses and sources of payment for nursing homes for 1987 and 1996. A central finding is that the role of Medicare in financing nursing home care has greatly expanded. Medicare payments represent 2 and 19 percent of the total for 1987 and 1996, respectively. As Medicare's role increased, there was an accompanying decline in the proportion of expenses paid out of pocket. In 1987, 45 percent was paid out of pocket versus 30 percent in 1996. Those nursing home residents using Medicare most heavily as a source of payment tended to exhibit very short stays (33 days on average), zero limitations in activities of daily living (ADLs), and no mental conditions.
- Published
- 2003
15. Personal characteristics and contextual factors associated with residential expenditures for individuals with mental retardation.
- Author
-
Rhoades JA and Altman BM
- Subjects
- Adult, Aged, Disability Evaluation, Female, Health Care Surveys, Humans, Intellectual Disability psychology, Intellectual Disability rehabilitation, Male, Middle Aged, Multivariate Analysis, Persons with Mental Disabilities rehabilitation, Surveys and Questionnaires, United States, Health Expenditures, Intellectual Disability economics, Medical Assistance economics, Persons with Mental Disabilities psychology, Residential Facilities economics
- Abstract
A multivariate analysis was done to determine the relative importance of facility, resident, and community characteristics to expenditures. Facility factors associated with higher expenditures included ownership, facility size, facility services, and location. Individuals with a greater number of activity of daily living limitations, developmental disabilities, and more severe levels of mental retardation had higher expenses. Findings could improve our understanding of the costs of long-term residential care, assisting us to economically and effectively bring this population into the community. Data used are from the 1987 National Medical Expenditure Survey Institutional Population Component.
- Published
- 2001
- Full Text
- View/download PDF
16. Where are the missing nursing homes?
- Author
-
Rhoades JA
- Subjects
- Aged, Bias, Certification, Data Interpretation, Statistical, Humans, Nursing Homes classification, United States, Health Care Surveys methods, Nursing Homes statistics & numerical data, Nursing Homes supply & distribution
- Published
- 2000
- Full Text
- View/download PDF
17. Prevention of elderly suicide. Physicians' assessment of firearm availability.
- Author
-
Kaplan MS, Adamek ME, and Rhoades JA
- Subjects
- Aged, Attitude of Health Personnel, Chi-Square Distribution, Clinical Competence statistics & numerical data, Confidence Intervals, Depression diagnosis, Depression therapy, Education, Medical, Education, Medical, Continuing statistics & numerical data, Female, Geriatric Assessment statistics & numerical data, Geriatric Psychiatry education, Health Care Surveys, Humans, Illinois, Logistic Models, Male, Medicine statistics & numerical data, Middle Aged, Odds Ratio, Patient Acceptance of Health Care, Risk Assessment, Sampling Studies, Specialization, Firearms statistics & numerical data, Health Services for the Aged statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Primary Health Care statistics & numerical data, Suicide Prevention
- Abstract
Introduction: Physicians have a unique role to play in the prevention of elder suicide, yet they may not be sufficiently attentive to the prominence of firearms in the rising trend in suicide by elder persons. This study sought to examine the extent to which physicians inquired about firearms with their depressed and suicidal elderly patients and further identified factors associated with physicians' likelihood of asking about firearms., Methods: A probability sample of 300 primary care physicians in Illinois was drawn from the American Medical Association Physician Masterfile. Physicians were chosen from the specialties most likely to be involved with elderly persons: internal medicine and family practice. A mailed questionnaire yielded a 63% response rate., Results: Although they were treating depressed and suicidal older patients, a sizable proportion of the respondents (42%) reported that they did not ask such patients or their family members whether they had access to a firearm. Several factors distinguished physicians who assessed for firearms from those who did not. The most salient predictors were: continuing medical education training in suicide risk assessment, expertise in geriatric mental health, confidence in diagnosing depression, having a patient mention suicide in the past year, and indicating patient reluctance as a barrier to mental health treatment., Discussion: Physicians working with depressed and suicidal elderly persons need to be informed about the prevalence of elder suicide and about the likelihood of elderly persons using firearms as a method of suicide. Effective suicide prevention will require physician training that directly addresses geriatric mental health and firearm suicide, in particular, at the student, residency, and continuing education levels.
- Published
- 1998
- Full Text
- View/download PDF
18. Carbon-13 nuclear magnetic resonance spectral analysis of tobramycin and related antibiotics.
- Author
-
Koch KF, Rhoades JA, Hagaman EW, and Wenkert E
- Subjects
- Aminoglycosides analysis, Carbon Isotopes, Hydrogen-Ion Concentration, Anti-Bacterial Agents analysis, Magnetic Resonance Spectroscopy
- Published
- 1974
- Full Text
- View/download PDF
19. Nebramycin: separation of the complex and identification of factors 4, 5, and 5'.
- Author
-
Koch KF, Davis FA, and Rhoades JA
- Subjects
- Hydrolysis, Streptomyces analysis, Anti-Bacterial Agents isolation & purification
- Published
- 1973
- Full Text
- View/download PDF
20. Structure of nebramycin factor 6, a new aminoglycosidic antibiotic.
- Author
-
Koch KF and Rhoades JA
- Subjects
- Amino Sugars, Chemical Phenomena, Chemistry, Glycosides, Anti-Bacterial Agents
- Published
- 1970
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.